These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24258833)

  • 21. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
    Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
    Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case report.
    Welsner M; Straßburg S; Taube C; Sutharsan S
    BMC Pulm Med; 2019 Apr; 19(1):76. PubMed ID: 30975115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the relationship between sweat chloride and lung function in cystic fibrosis.
    Heltshe SL; Mayer-Hamblett N; Rowe SM
    Chest; 2013 Oct; 144(4):1418. PubMed ID: 24081360
    [No Abstract]   [Full Text] [Related]  

  • 24. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
    Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
    Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.
    Dilokthornsakul P; Hansen RN; Campbell JD
    Eur Respir J; 2016 Jun; 47(6):1697-705. PubMed ID: 27126691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystic fibrosis in an era of genomically guided therapy.
    Barrett PM; Alagely A; Topol EJ
    Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
    McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
    Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the predictive ability of sweat chloride.
    Heltshe SL; Rowe SM; Mayer-Hamblett N
    J Cyst Fibros; 2014 Jan; 13(1):118. PubMed ID: 23920003
    [No Abstract]   [Full Text] [Related]  

  • 30. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
    Dryden C; Wilkinson J; Young D; Brooker RJ;
    Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males.
    Aalbers BL; Hofland RW; Bronsveld I; de Winter-de Groot KM; Arets HGM; de Kiviet AC; van Oirschot-van de Ven MMM; Kruijswijk MA; Schotman S; Michel S; van der Ent CK; Heijerman HGM
    J Cyst Fibros; 2021 Jan; 20(1):e7-e11. PubMed ID: 32448708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
    Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J
    Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
    Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
    Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Oct; 144(4):1418-1419. PubMed ID: 24081359
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation.
    Hebestreit H; Sauer-Heilborn A; Fischer R; Käding M; Mainz JG
    J Cyst Fibros; 2013 Dec; 12(6):599-603. PubMed ID: 23757359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.
    Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J
    BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
    Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA
    Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.